1Bakshi RP,Galande S, Muniyappa K. Functional and regulatory charactefistics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol,2001,36(1) :1-37.
2Liu D, Huang CL, Kameyama K et al. Topoisomerise Halpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer,2002,94( 8 ) :2239-2247.
3Syahmddin E, Oguri T, Takahashi T, et al. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung caneer. Jpn J Cancer Res. 1998,89( 8 ) :855-861.
4Brana MF, Cacho M, Gradillas A, et al. lnterealators as anticancer drugs. Curr Pharm Des,2001,7(17) :1745-1780.
6Nitiss JL . DNA topoisomerases in caner chemotherapy: using enzymes to generate seleetive DNA damage. Curr Opin lnvestig Drags,2002,3(10) :1512- 1516.
7Liu B, Staten F,D, lwamura T, et al. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res,2001 ,99(2 ):179-186.
8Ogiso Y, Tomida A,Tsumo T. Nuclear localization of proteasomes participates in stress-inducible resistance of solid mmor cells to topoisomerase II- directed drugs. Cancer Res, 2002,62 ( 17 ) :5008-5012.
9Matsurmoto Y, Takano H, Kunishio K,et al. Expression of drug resistante genes in VP-16 and mAMSA-selected human carcinoma cells. Jpn J Cancer Res,2001,92(7) :778-784.
10Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res,2003,63 ( 15 ) :4527-4532.
